Peritoneal fibrosis (PF) is a pathophysiological condition caused by a variety of pathogenic
factors. The most important features of PF are mesothelial–mesenchymal transition and …

Abstract Background Mesenchymal stem cells (MSCs) provide potential treatments for
peritoneal fibrosis. However, MSCs cultured in media containing serum bring risks of …

Conclusions In preclinical studies, the use of stem cells is associated with improved
peritoneal fibrosis. This may provide an important foundation to support future translational …

Peritoneal fibrosis (PF) is invariably observed in patients undergoing long-term peritoneal
dialysis (PD). The condition is thought to occur in response to a variety of insults, including …

Long-term peritoneal dialysis (PD) causes chronic peritoneal damage. Peritoneal
mesothelial cells (PMCs) play an important role in peritoneal function. We investigated the …

Peritoneal fibrosis is a chronic, progressive progress, which is associated with ultrafiltration
failure. In the development of peritoneal fibrosis, Epithelial to mesenchymal transition is an …

Marked thickening of the peritoneum and vasculopathy in the submesothelial compact zone
have been reported in long-term peritoneal dialysis patients. Bone marrow (BM)-derived cell …

Background Mesothelial cell injury plays an important role in peritoneal fibrosis. Present
clinical therapies aimed at alleviating peritoneal fibrosis have been largely inadequate …

Mesenchymal stem cells (MSCs) are multipotent adult stem cells that have regenerative
capability and exert paracrine actions on damaged tissues. Since peritoneal fibrosis is a …

Long-term peritoneal dialysis (PD) can lead to fibrotic changes in the peritoneum,
characterized by loss of mesothelial cells (MCs) and thickening of the submesothelial area …